Weight Loss

These peptides, known as incretin mimetics or GLP-1 receptor agonists (and multi-agonists), mimic gut hormones to regulate blood sugar, slow gastric emptying, suppress appetite, and promote significant fat loss. They enhance insulin secretion, reduce hunger, and support metabolic health, leading to substantial weight reduction when used as an adjunct to diet and exercise under medical supervision.

Retatrutide

Retatrutide is an investigational triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. By adding glucagon receptor activation, it boosts energy expenditure, promotes fat metabolism, and amplifies appetite suppression beyond dual or single agonists. In phase 2 and recent phase 3 trials (e.g., TRIUMPH program, as of late 2025), retatrutide has demonstrated the highest reported weight loss among these, with averages of 22-28% (up to ~28.7% at higher doses over 68 weeks), including substantial reductions in liver fat and improvements in related conditions like osteoarthritis pain. It remains in late-stage development (not yet FDA-approved as of December 2025) but shows promise as the most potent option in this class.

Tirzepatide

Tirzepatide is a dual agonist peptide that targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action further enhances insulin secretion, reduces appetite more effectively, and may lead to improved outcomes compared to single-agonist therapies. Tirzepatide (e.g., Zepbound for weight management, Mounjaro for diabetes) is FDA-approved and typically delivers greater weight loss than semaglutide, with average reductions of 18-21% over 72 weeks in trials (e.g., ~20% at higher doses). It is noted for superior efficacy in obesity management, often with comparable or slightly different gastrointestinal side effect profiles.

Semaglutide

Semaglutide is a GLP-1 receptor agonist (a synthetic peptide analog of glucagon-like peptide-1). It mimics the natural GLP-1 hormone to enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety. This results in reduced calorie intake and improved metabolic function. Semaglutide (e.g., Wegovy for weight management, Ozempic for diabetes) is FDA-approved and has shown average weight loss of around 14-15% over 68 weeks in clinical trials for people with obesity or overweight, with many achieving 10-20% reductions. It also offers cardiovascular benefits.

More Info

These peptides are administered as once-weekly subcutaneous injections and are most effective under medical guidance, with common side effects including gastrointestinal issues (nausea, diarrhea) that often decrease over time. Individual results vary, and they are not suitable for everyone—consult a healthcare provider for personalized advice.